On October 14, 2025, 4D Molecular Therapeutics announced that the Cystic Fibrosis Foundation will provide up to $11 million in additional funding, with an initial tranche of $7.5 million, to accelerate the development of its 4D‑710 gene‑therapy program for cystic fibrosis lung disease.
4D‑710 is a durable, redosable, variant‑agnostic therapy that delivers a codon‑optimized CFTR transgene via an aerosolized AAV vector (A101). The program has already demonstrated successful delivery and expression of CFTR throughout the lungs in patients, and it has received Rare Pediatric Disease and Orphan Drug Designations from the FDA.
The funding agreement includes the creation of a Joint Steering Committee composed of senior clinical development and regulatory experts to enhance strategic planning and coordination of 4D‑710’s development. The CF Foundation will invest up to $11 million in equity in two tranches, with the second tranche contingent on specific clinical milestones, and the first tranche of $7.5 million closed in October 2025.
This partnership not only injects capital into the program but also provides technical support and governance that can accelerate the transition of 4D‑710 from Phase 1 to Phase 2, potentially shortening the development timeline and improving the company’s cash runway into 2028.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.